EcoDrugPlus

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSMMSG00000000993
Gene Symbol: PSMB10
1 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSMMSG00000009599
Gene Symbol: PSMB2
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSMMSG00000020218
Gene Symbol: PSMB3
1 Cross references
234 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSMMSG00000017613
Gene Symbol: PSMB4
1 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSMMSG00000002310
Gene Symbol: PSMB5
1 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSMMSG00000007683
Gene Symbol: PSMB6
1 Cross references
195 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSMMSG00000017573
Gene Symbol: PSMB7
1 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSMMSG00000022217
Gene Symbol: PSMB8
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSMMSG00000022236
Gene Symbol: PSMB9
1 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSMMSG00000012141
Gene Symbol: PSMD2
1 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSMMSG00000012473
Gene Symbol: PSMC1
1 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSMMSG00000016077
Gene Symbol: PSMC2
1 Cross references
227 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).